Fig. 3: Tumor responses. | Nature Communications

Fig. 3: Tumor responses.

From: Induction chemotherapy plus camrelizumab followed by concurrent chemoradiotherapy in unresectable locally advanced esophageal squamous cell carcinoma: a single-arm phase II trial

Fig. 3: Tumor responses.The alternative text for this image may have been generated using AI.

a Contrast-enhanced CT images from a representative patient showing significant tumor shrinkage following induction chemotherapy plus camrelizumab and sustained partial response after concurrent chemoradiotherapy. b Maximum change in target lesion sizes from baseline assessed per RECIST 1.1 after induction chemotherapy plus camrelizumab (n = 46). Three patients who did not receive chemoradiotherapy were excluded from the 49 intention-to-treat patients. c Maximum change in target lesion sizes from baseline assessed per RECIST 1.1 after concurrent chemoradiotherapy (n = 44). Two patients who died before overall response evaluation were excluded from the 46 per-protocol patients. d Onset of response, duration of response, and outcome (n = 49). Tumor response was assessed per RECIST 1.1. Source data are provided as a Source Data file. CT computed tomography, PD-L1 programmed cell death-ligand 1, CPS combined positive score, RECIST Response Evaluation Criteria in Solid Tumors.

Back to article page